title: [Epidemiology of acromegaly in Spain].
abstract: Epidemiology of acromegaly in Spain does not differ from that reported in other published series. Prevalence rate is approximately 60 cases per million, peak incidence occurs in middle age, more women are affected (61%), and there is a substantial delay between occurrence of the first symptoms and diagnosis. Studies REA (Spanish Acromegaly Registry) and OASIS analyzed the epidemiology, clinical characteristics, and management of the disease in Spain. Surgery, performed in more than 80% of patients, has been (and continues to be) the main treatment for the past four decades. In the past decade, however, more patients have received somatostatin analogs (SSAs) as first-line treatment. Use of radiation therapy has significantly decreased in recent decades. Somatostatin analogs (SSAs) are the most commonly used drugs, administered to 85% of patients; however, only 12%-15% continue on drug treatment alone. The surgical remission rate was 38.4% in the last decade, with a significant improvement over decades. Preoperative treatment with SSAs has no influence on surgical cure rates. Second-line therapies used after surgical failure in the past decade included SSAs in 49% of patients, repeat surgery in 27%, radiotherapy in 11%, pegvisomant in 15%, and dopamine agonists in 5%. Mean cost of acromegaly treatment was 9.668€ (data estimated in 2009 and adjusted in 2010), of which 71% was due to the cost of SSAs. Patients treated with pegvisomant have a more aggressive form of the disease and higher comorbidity rates.
authors.affiliation: Servicio de Endocrinología, Institut Universitari Dexeus, Barcelona, España. Electronic address: 30064gsl@comb.cat.
authors.forename: Gemma
authors.initials: G
authors.lastname: Sesmilo
mesh_terms: D000172:Acromegaly / Q000188:drug therapy / Q000191:economics / Q000453:epidemiology* / Q000209:etiology; D000236:Adenoma / Q000150:complications / Q000453:epidemiology / Q000532:radiotherapy / Q000601:surgery; D017677:Age Distribution; D015897:Comorbidity; D016371:Cranial Irradiation; D018491:Dopamine Agonists / Q000627:therapeutic use; D016527:Drug Costs; D005260:Female; D049912:Growth Hormone-Secreting Pituitary Adenoma / Q000150:complications / Q000453:epidemiology / Q000532:radiotherapy / Q000601:surgery; D019382:Human Growth Hormone / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D007016:Hypophysectomy; D015994:Incidence; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D010911:Pituitary Neoplasms / Q000150:complications / Q000453:epidemiology / Q000532:radiotherapy / Q000601:surgery; D015995:Prevalence; D000091402:Prohibitins; D012042:Registries; D012189:Retrospective Studies; D017678:Sex Distribution; D013004:Somatostatin / Q000031:analogs & derivatives / Q000191:economics / Q000627:therapeutic use; D013030:Spain / Q000453:epidemiology
chemical_list: D018491:Dopamine Agonists; C000717331:PHB2 protein, human; D000091402:Prohibitins; D019382:Human Growth Hormone; D013004:Somatostatin; C406545:pegvisomant